PARLIAMENTARY WRITTEN QUESTION
(11 February 2025)
Question Asked
Asked by:
Blake Stephenson (Conservative)
Answer
AstraZeneca’s decision not to invest in Speke is deeply disappointing. The Government regularly reviews it’s grant process and routinely seeks applicant feedback. The Government also continues to engage positively with AstraZeneca, including on the new Industrial Strategy and Life Sciences Sector Plan, due to be published in late Spring. This will set out a comprehensive plan of how the Government intends to drive growth in the sector. Support includes the Life Sciences Innovative Manufacturing Fund, which will allocate up to £520 million to deliver economic growth and build health resilience.
Answered by:
()
Contains Parliamentary information licensed under the Open Parliament Licence v3.0.